What is the typical lead time for orders?

The average lead time is one month, especially during peak seasons.

What types of pharmaceutical products does the company manufacture?

The company manufactures infusions, capsules, granules, tablets, oral liquids, and more.

What is the annual production capacity?

Yearly output has reached more than 1200 million bottles for key products.

Furosemide Tablet 20mg GMP Manufacturer

Name: Furosemide Tablet 20mg GMP Manufacturer
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2107916872

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

Negotiable

100,000 tablet

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

20mg

Suitable for

Elderly, Adult

State

Solid

Shape

Tablet

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

GMP

Yes

Transport Package

Cartons

Specification

20mg

Trademark

SHIMEN

Origin

Heibi

HS Code

3004909099

Production Capacity

1000000000 Tabletss/Year

Key features

GMP Certified Manufacturer: Produced in a large-sized foreign invested enterprise with GMP approval by SFDA of China.

Established Pharmaceutical Brand: Shijiazhuang No.4 Pharmaceutical Co., Ltd. established in 1948 with over 3000 employees.

High Production Capacity: Yearly output exceeds 1200 million bottles for key products, leading in China.

Global Market Presence: Products sold to South America, Africa, Asia, Oceania, and Middle East regions.

Diverse Product Portfolio: Manufactures 7 series medicines including infusions, capsules, granules, and tablets.

Flexible Payment Terms: Accepts LC and T/T payment methods for international transactions.

Multiple Export Options: Supports FOB, CFR, CIF, CIP, and EXW international commercial terms.

Fast Peak Season Delivery: Average lead time is one month during peak seasons.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.